Copy
NewsTechno #6 by SATT Ouest Valorisation
View this email in your browser
Dear partners,
We are pleased to send you the latest issue of our
NEWSTECHNO. The Biofit event will take place on December, 1st and 2nd. Here is an overview of the technologies that are available for companies in the healthcare sector, and more specifically in personalized medicine.
Please feel free to share this 
NEWSTECHNO with your industrial contacts.
Enjoy the reading
Personalized (or tailored) medicine: what does it mean?

Since the early 2000s, medical research is working on tailored medicine, with the aim of understanding the differences between patients in order to administrate them the adequate treatment.
In 2013, Roche Company has introduced on the market a new treatment bringing hope for patients with metastasic melanoma, using the term Personalized Medicine. All patients bearing BRAF V600E mutation will respond to this medicine. In fact, definition of tailored medicine encompasses pharmacogenetics queries. Lots of parameters shall be taken into account like patient specific response to a treatment, physiologic status or anatomic specificity.
Several tools are now available to reach this purpose. For instance: Next-Generation Sequencing (NGS) allows a rapid, cheap and accurate genetic mapping of mutation; 3D cell culture brings a new model to evaluate response to a treatment directly throughout patient-cells; Imaging processing methods allow the radiotherapy treatment to be adapted to the patient’s organ conformation for more efficiency.
In this news, we feature five of our technologies which address this tailored medicine issue.


 
Clément Jouanneau,
Technology Transfer Officer
- Genetic Engineering
# 6 : Tailored Medicine
Meet up with SATT Ouest Valorisation and its technologies on  :


December, 1st and 2nd at the Biofit event, in Strasbourg. You will find us at Booth F8, shared with the "Réseau SATT".


And in parallel with the fair, we are looking forward to welcoming you at the TechnoMarket Life Sciences event and presenting you technologies through posters and pitches.


Find Ouest Valorisation technologies presented at Biofit on the Reseau des SATT technologies search engine, by using the keyword BIOFIT.
New tailored medicine in metastasic melanoma

Metastatic Melanoma is one of the most aggressive form of skin cancer. Combination of targeted therapies or immune checkpoint therapies has increased the Overall Survival (OS) of patients with metastatic Superficial Spreading Melanoma (SSM). Presently, ongoing trials consider the use of tri-therapies to extend the time of patient OS. Adjuvant therapies are also under investigation.

The issue is to propose a new class of therapy which is RNA-targeted, to increase the duration of the patient survival and to propose a new target for other types of melanoma.

The solution brought by scientists comes from the identification of a mRNA that dampens the tumor suppressor activity of a miRNA and consists in restoring the activity of this ‘natural brake’ avoiding miRNA sequestration using Target Site Blockers (TSB, 16 modified nucleotides single strand).
  • Lower dose of chemotherapy
  • Combination with targeted and immune checkpoint therapies possible
  • Independent of BRAF/ NRAS mutations
  • Natural mechanism – low resistance expected
  • No side effect in vivo
This technology has been developed by the Institut de Génétique et Développement de Rennes
Prediction of toxicity

An innovative platform has just been developed to identify areas with a toxicity risk, in order to optimize the planning of a treatment. It allows the mapping – on the patients’ images – of organs subregions involved in toxicity and then to infer patient-specific planning constraints.

This method is based on the use of a toxicity prediction model, established from real data. Therefore, the model contains a collection of atlas representing the anatomical subregions responsible for the observed toxicity.

This atlas is used to propagate the subregions’ contours on the clinical image of the patient, and thereby adapt specifically and individually the treatment plan. Then the system provides a toxicity prediction index of the planned traitement.
  • Improvement of the treatments efficiency by reducing the side effects
  • Solution allowing a prediction of toxicity
This technology has been developed by the Laboratoire Traitement du Signal et de l'Image
 
Glioblastoma prognostic markers
GBM is the most common and aggressive primary brain tumor in adults. Its prognosis remains extremely poor, despite multimodal treatment by surgery, radiotherapy and chemotherapy with temozolomide (standard treatment). Determining robust signatures and clinically relevant molecular classifiers of GBM is a real challenge for personalized medicine success.
The technology concerns glioblastoma (GBM) prognosis markers. Based on methylation status of MGMT promoter (reference marker) and associated to DGKI methylation markers, this new tool can stratify with higher sensitivity cohorts which will respond better to standard treatment (STUPP protocol).
This epigenetic signature is a new tool bringing more confidence to physicians in anticipating patients’ response to standard treatment.


This technology has been developed by the Institut de Génétique et Développement de Rennes
Organotypic culture cells for kidney cancer
Most of kidney cancers are highly vascularised tumor. To fight against its anarchic growth, physicians use drugs based on the inhibition of receptor for angiogenesis. Nevertheless, most of them have no effect on specific patient types, so it remains a big challenge to provide new therapies able to treat these patients.
The technology developed by research team brings a new tool to determine if the patient will respond to standard treatment. The project involves from a biopsy, to provide a sample of tumor to research team, which have know-how to obtain a whole tissue from a single cell (organotypic culture). Several drugs are tested and the most effective (combination or alone) will be used on patient. The results obtained with the kidney organotypic culture will help for the establishment of the individual therapy.


This technology has been developed by the Institut de Génétique et Développement de Rennes
To discover the other technologies in the Health sector and the 200 technologies available in Ouest Valorisation's portfolio, click and have a look at our Technologies Map.
The technologies presented in this NewsTechno have been developed by the following laboratories :
To learn more about the laboratories' skills :
  • Plug in Labs Ouest provides a way to search interactively for any competency within the Public Research Laboratories of Bretagne.
  • Territoires d'Innovation lists the laboratories' competencies of the Pays de la Loire area.
The research institutions that are located in Brittany and Pays de la Loire own several technological platforms. These platforms enable the industry to access valuable skills and facilities, in order to design and test the innovations.
To keep up-to-date with the latest technologies...
Website
Twitter
LinkedIn
And now you can have a broad view of technologies offers from all French SATT on the Réseau SATT website.
Copyright © 2015 SATT Ouest Valorisation, All rights reserved.

communication@ouest-valorisation.fr

SATT Ouest Valorisation
14C rue du Pâtis Tatelin,
Métropolis 2, CS 80 804
35708 Rennes Cedex


unsubscribe from this list